As of November 9, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Cryo Cell International Inc. The largest reported stake is Camac Partners, LLC's, at 6.8%. 2 filings are on record since March 25, 2026 (Schedule 13D/A, July 7, 2026).
Sell to companies like Cryo Cell International Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Cryo Cell International Inc has 2 Schedule 13D or 13G filings on record since 2026-03-25. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Camac Partners, LLC | 6.8% | 551,081 | SCHEDULE 13D/A, 2026-07-07 | 2026-07-02 |
Holding shares or following this stake? See who's behind Cryo Cell International Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Cryo Cell International Inc and the records around it.
Companies that share a holder
- Camac Partners, LLC also filed stake reports on 1 other company: TruBridge, Inc (Jul 2026)
Watch Cryo Cell International Inc
Get an email when Cryo Cell International Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Cryo Cell International Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Cryo Cell International Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Cryo Cell International Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Camac Partners, LLC | 0 | 551,081 | 0 | 551,081 | SCHEDULE 13D/A, 2026-07-07 |
| Camac Capital, LLC | 0 | 551,081 | 0 | 551,081 | SCHEDULE 13D/A, 2026-07-07 |
| Camac Fund, LP | 0 | 551,081 | 0 | 551,081 | SCHEDULE 13D/A, 2026-07-07 |
| Eric Shahinian | 0 | 551,081 | 0 | 551,081 | SCHEDULE 13D/A, 2026-07-07 |
The latest filing identifies Cryo Cell International Inc by CUSIP 228895108 and gives its principal executive office as 700 BROOKER CREEK BLVD, Suite 1800, Oldsmar, FL 34677 (SCHEDULE 13D/A, 2026-07-07).
Source of funds (Item 3)
The Shares purchased by Camac Fund were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). The aggregate purchase price of 551,081 Shares beneficially owned by Camac Fund is approximately $1,807,998 including brokerage commissions.Camac Partners, LLC, SCHEDULE 13D/A, 2026-07-07
Purpose of Transaction (Item 4)
Camac Partners, LLC
The Reporting Persons purchased the securities of the Issuer reported herein based on the Reporting Persons' belief that such securities, when purchased, were undervalued and represented an attractive investment opportunity. Depending upon overall market conditions, other investment opportunities available to the Reporting Persons, and the availability of securities of the Issuer at prices that would make the purchase or sale of such securities desirable, the Reporting Persons may endeavor to (i) increase or decrease their respective positions in the Issuer through, among other things, the purchase or sale of securities of the Issuer on the open market or in private transactions or otherwise, on such terms and at such times as the Reporting Persons may deem advisable and/or (ii) enter into transactions that increase or hedge their economic exposure to the securities of the Issuer without affecting their beneficial ownership of the Shares. No Reporting Person has any present plan or proposal which would relate to or result in any of the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon completion of any of the actions discussed herein. The Reporting Persons intend to review their investments in the Issuer on a periodic basis and may from time to time engage in communications and discussions with management and the Board of Directors of the Issuer (the "Board"), other stockholders of the Issuer and …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-07-07; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2026-03-25 | Camac Partners, LLC | 5.3% | SCHEDULE 13D |
| 2026-07-07 | Camac Partners, LLC | 6.8% | SCHEDULE 13D/A |
Questions about who owns Cryo Cell International Inc
Who owns Cryo Cell International Inc?
On this page, one holder's latest ownership filing reports 5% or more of Cryo Cell International Inc: Camac Partners, LLC (6.8%, Schedule 13D/A, filed 2026-07-07).
When did Camac Partners, LLC buy into Cryo Cell International Inc?
The filings give report dates, not purchase dates. The earliest filing from Camac Partners, LLC on this page is the Schedule 13D, filed 2026-03-25, reporting 5.3%; its latest, Schedule 13D/A filed 2026-07-07, reports 6.8%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 2 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Cryo Cell International Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.